Immunotherapy of B‐cell non‐Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model
Authors:
Open Access
- 12 April 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (11) , 2623-2632
Abstract
Bispecific antibodies are promising agents for immunotherapy. Here, we describe a quadroma‐based trifunctional bispecific antibody binding the chemokine receptor CXCR5 and the T‐cell antigen CD3 that efficiently prevents tumor growth in a mouse B‐cell lymphoma model. CXCR5 regulates the tissue homeostasis of mature B cells and is highly expressed on B‐cell non‐Hodgkin and lymphocyte‐predominant Hodgkin lymphoma, as well as on a subset of CD4+ T cells known as follicular T‐helper cells. In vitro, the bispecific CXCR5::CD3 antibody efficiently recruited effector T cells to CXCR5 expressing B cells and induced a co‐stimulation‐independent activation of CD8+ and CD4+ T cells as demonstrated by the de novo expression of CD25 and CD69, and secretion of the cytokines IFN‐γ, TNF‐α, IL‐6 and IL‐10 by peripheral blood mononuclear cells. Notably, at low antibody concentrations, CXCR5::CD3 displayed a significantly higher cytotoxic activity against autologous B cells than its parental antibodies or rituximab. In vivo imaging revealed that CXCR5::CD3 and its parental CXCR5 antibody efficiently prevent tumor growth in a xenograft model of B‐cell lymphoma in mice and prolong their survival. Taken together, our results identify CXCR5 as a promising target for antibody‐based therapies in the treatment of B‐cell malignancies.Keywords
Funding Information
- the Helmholtz Alliance on Immunotherapy of Cancer
- Innochem (LSHB-CT-2005-518167)
This publication has 28 references indexed in Scilit:
- Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis aloneAnnals of Oncology, 2012
- Anti-CD20 Antibody Therapy for B-Cell LymphomasNew England Journal of Medicine, 2012
- Rituximab resistanceBest Practice & Research Clinical Haematology, 2011
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- The CXCR5 Chemokine Receptor Is Expressed by Carcinoma Cells and Promotes Growth of Colon Carcinoma in the LiverCancer Research, 2006
- Follicular B helper T cell activity is confined to CXCR5hiICOShi CD4 T cells and is independent of CD57 expressionEuropean Journal of Immunology, 2006
- Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein × anti-CD3 diabodyLeukemia, 2004
- Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)Journal of Histochemistry & Cytochemistry, 2001
- Mechanisms of Action and Overview of OKT3Therapeutic Drug Monitoring, 1995
- Differentiation‐specific expression of a novel G protein‐coupled receptor from Burkitt's lymphomaEuropean Journal of Immunology, 1992